New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 18, 2014
07:28 EDTDHR, DGX, RHHBY, ABT, JNJ, LHCLFS review potential negative for Quest, LabCorp, says Piper Jaffray
Piper Jaffray views the Centers for Medicare & Medicaid Services' plan to revalue Clinical Lab Fee Schedule test codes as a potential negative for Quest Diagnostics (DGX) and LabCorp (LH) as well as diagnostic manufacturers like Abbott (ABT), Danaher (DHR), Johnson & Johnson (JNJ) and Roche (RHHBY). Piper says Quest and LabCorp both have around 12% of revenue exposure to CLFS, which it feels presents risk for additional reimbursement pressure in FY15. The review follows an Office of Inspector General report that found CMS paid between 18%-30% higher for 20 high volume/high expenditure tests than state and federal plans.
News For DGX;LH;ABT;DHR;JNJ;RHHBY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
November 14, 2014
14:53 EDTJNJ, RHHBYCVS Express Scripts implementing drug price controls, says Cleveland Research
Cleveland Research believes that CVS (CVS) and Express scripts are implementing rebates and price controls on drug. The firm expects the companies to increase their focus on controlling durg prices next year, and adds that they have already itnroduced prior authorization criteria for hepatitis drug. Publicly traded drug companies include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Makers of hepatits c drugs include AbbVie (ABBV) and Gilead (GILD),
13:27 EDTRHHBYRoche reports FDA nod for Avastin in platinum-resistant recurrent ovarian cancer
Subscribe for More Information
07:14 EDTDGXAmerican College of Rheumatology is holding a meeting
2014 ACR/ARHP Annual Meeting is being held in Boston on November 14-19.
November 13, 2014
16:28 EDTJNJGeron announces global strategic collaboration with Janssen Biotech
Geron (GERN) announced that the company has entered into an exclusive worldwide license and collaboration agreement with Janssen Biotech, a Johnson & Johnson (JNJ) company, to develop and commercialize, imetelstat, Geron's telomerase inhibitor product candidate, for oncology, including hematologic malignancies, and other human therapeutics uses. Imetelstat is a modified oligonucleotide that is currently in early phase clinical development for myelofibrosis, or MF, and may have activity in other hematologic myeloid malignancies such as myelodysplastic syndrome, or MDS, and acute myelogenous leukemia, or AML. Under the terms of the agreement, Geron will receive an initial payment of $35M due after the applicable waiting periods under the Hart-Scott Rodino Act and is eligible to receive additional payments up to a potential total of $900M for the achievement of development, regulatory and commercial milestones, as well as royalties on worldwide net sales. Certain regulatory, development, manufacturing and promotional activities will be managed through a joint governance structure, with Janssen responsible for operational implementation of these activities. All sales will be booked by Janssen.
11:54 EDTJNJJanssen announces FDA approved sNDA for INVEGA SUSTENNA
Subscribe for More Information
10:44 EDTJNJMallinckrodt news on generic Concerta positive for Actavis, says BMO Capital
Subscribe for More Information
10:01 EDTLHOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: ATK (ATK) downgraded to Hold from Buy at Argus... Adeptus Health (ADPT) downgraded to Hold from Buy at Deutsche Bank... American Woodmark (AMWD) downgraded to Neutral from Buy at Longbow... Avnet (AVT) downgraded to Sell from Neutral at Goldman... Baxano Surgical (BAXS) downgraded to Sell from Buy at Summer Street... Beazer Homes (BZH) downgraded to Neutral from Overweight at JPMorgan... Bristol-Myers (BMY) downgraded to Equal Weight from Overweight at Morgan Stanley... Centene (CNC) downgraded to Market Perform from Outperform at FBR Capital... Cherry Hill Mortgage (CHMI) downgraded to Equal Weight from Overweight at Barclays... Discover (DFS) downgraded to Hold from Buy at Deutsche Bank... Fleetmatics (FLTX) downgraded to Neutral from Buy at BofA/Merrill... Gazprom (OGZPY) downgraded to Neutral from Overweight at JPMorgan... Jabil Circuit (JBL) downgraded to Neutral from Buy at Goldman... LabCorp (LH) downgraded to Hold from Buy at Deutsche Bank... Laredo Petroleum (LPI) downgraded at BMO Capital... Macy's (M) downgraded to Market Perform from Outperform at Wells Fargo... Madison Square Garden (MSG) downgraded to Equal Weight from Overweight at Morgan Stanley... Marvell (MRVL) downgraded to Sell from Neutral at Goldman... Meritor (MTOR) downgraded to Neutral from Overweight at Piper Jaffray... Swedbank (SWDBY) downgraded to Underperform from Sector Perform at RBC Capital... TransGlobe (TGA) downgraded to Sector Perform from Outperform at Scotia Capital... UIL Holdings (UIL) downgraded to Hold from Buy at Argus... Verint Systems (VRNT) downgraded to Fair Value from Buy at CRT Capital... ZAIS Financial (ZFC) downgraded to Equal Weight from Overweight at Barclays.
10:01 EDTDGXOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
06:16 EDTLH, DGXLabCorp downgraded to Hold from Buy at Deutsche Bank
Deutsche Bank downgraded LabCorp (LH) to Hold saying revenue synergies from the Covance (CVD) acquisition are "hard to envision." The firm believes LabCorp is now less of a pure play in the Clinical Labs space and lowered its price target for shares to $115 from $120. Deutsche coupled the downgrade with an upgrade of peer Quest (DGX).
06:13 EDTLH, DGXQuest Diagnostics upgraded to Buy from Hold at Deutsche Bank
Subscribe for More Information
November 12, 2014
11:17 EDTRHHBYLeerink major pharma & biotech analysts hold analyst/industry conference call
Subscribe for More Information
10:00 EDTDHROn The Fly: Analyst Upgrade Summary
Subscribe for More Information
07:22 EDTRHHBYAssociation of Molecular Pathology is holding annual meeting
2014 Annual Meeting of AMP is being held in National Harbor, Maryland on November 12-15.
05:42 EDTDHRDanaher upgraded to Outperform from Market Perform at FBR Capital
Subscribe for More Information
November 11, 2014
15:43 EDTRHHBYLeerink major pharma & biotech analysts hold analyst/industry conference call
Subscribe for More Information
November 10, 2014
16:07 EDTRHHBYUBS to hold a conference
UBS European Conference is being held in London, England on November 11-12.
07:44 EDTJNJJohnson & Johnson looks for acquisitions to help expand in China, WSJ says
Subscribe for More Information
November 7, 2014
17:00 EDTLHMarket ends week higher after upbeat U.S. data, hint at ECB easing
Stocks finished the week higher and near record levels as several better than expected U.S. economic data points boosted shares. MACRO NEWS: In the U.S., weekly jobless claims, a manufacturing index for October, and factory orders for September all beat expectations. The nonfarm payrolls report showed fewer than expected jobs were added last month, but the figures from the prior two months were upwardly revised... European Central Bank President Mario Draghi said the ECB Governing Council was unanimous in its commitment to use unconventional instruments if needed to boost the euro zone's economy. Meanwhile, some possible "green shoots" emerged in Europe, as France reported that its manufacturing output had risen 0.6% in September versus August. Furthermore, Western European car sales surged 5.5% in October versus the same period a year earlier, Reuters reported, citing industry data. There was, however, some negative news out of Europe, as Germany said that its factory orders had increased just 0.8% in September, following a revised 4.2% slump in August. Economists had expected the orders to jump 2.3%. Also, the European Commission cut its 2014 GDP growth forecast for the EU to 0.8% from its previous forecast for a 1.2% gain. COMPANY NEWS: Tesla (TSLA), Chinese e-commerce giant Alibaba (BABA), Archer Daniels Midland (ADM), International Paper (IP), Whole Foods (WFM), and upscale accessories and apparel maker Kate Spade (KATE) were among the stocks that climbed following their results. Conversely, multi-level marketer Herbalife (HLF), Priceline (PCLN), Michael Kors (KORS), IT security company FireEye (FEYE), and chip maker Qualcomm (QCOM) fell following their quarterly reports... In takeover news, clinical laboratory company LabCorp (LH) said it would buy drug development services company Covance (CVD) for $105.12 per share in cash and stock, and marketing services company Sapient (SAPE) agreed to be acquired by French advertising giant Publicis (PUBGY) for $25.00 per share in cash... Shares of a number of hospital owners, including Tenet Healthcare (THC), Community Health (CYH), and HCA Holdings (HCA) fell after Republicans won control of the U.S. Senate. Republicans have promised to seek to repeal most parts of the Affordable Care Act, which benefits hospitals by reducing the number of uninsured patients that use their services. Additionally, the Supreme Court today agreed to hear a lawsuit challenging the federal government's right to subsidize the health insurance premiums of Americans who buy health insurance through the federal exchange set up by the Act... The Justice Department sued to block the acquisition of Screenvision, which provides solutions related to cinema advertising, by movie theater ad network National CineMedia (NCMI), sending its stock lower. Movie theater operator Carmike Cinemas (CKEC), which owns a 19% “profits interest" in the holding company for Screenvision, also slid following the news. INDEXES: For the week, the Dow is up 1.04% to 17,573.93, the Nasdaq is up 0.03% to 4,632.53, and the S&P 500 is up 0.66% to 2,031.92.
16:07 EDTJNJJohnson & Johnson completes acquisition of Alios BioPharma
Subscribe for More Information
13:21 EDTLHLabCorp management to meet with Craig-Hallum
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use